SHANGHAI, March 26, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced that a preclinical study of innovative pretreatment regimens for cell therapy will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30 in Chicago.
This study indicated that hydroxychloroquine (HCQ) could significantly increase the tumor-killing effects via elevating the membrane MHC-I protein levels of tumor cells without affecting TILs'proliferation. In addition, its effect on surface PD-L1 expression was not significant compared with IFN-γ. These results provide preclinical evidence for HCQ pretreatment of the adoptive cell therapy of TILs in clinical trials.
Details of the poster presentation are below:
Abstract Number: 5827
Abstract Title: Hydroxychloroquine increases the tumor killing efficiency via elevating the membrane MHC-I protein levels of tumor cells
Session Title: Immunomodulatory Agents and Interventions
Location: Poster Section 29
Poster Board Number: 3
Poster Presentation Time: 2:00 PM - 5:00 PM CST, April 29, 2025
About Juncell Therapeutics
Juncell Therapeutics is a biotech dedicated to developing high-quality, accessible TIL cell therapies for the treatment of solid tumors. Juncell Therapeutics has established its proprietary DeepTIL® cell expansion and NovaGMP® gene modification technology platforms, which are designed to address the key challenges of conventional TIL therapies, making TILs "robust, competent, affordable, and accessible." Two clinical-stage TIL therapies have demonstrated promising safety and efficacy in the treatment of ten types of heavily pretreated advanced solid tumors, including lung cancer, triple-negative breast cancer, pancreatic cancer, high-grade glioma, ovarian cancer, endometrial cancer, cervical cancer, head and neck cancer, bile duct cancer and melanoma. 7 of these late-stage tumor patients have achieved complete response, and the longest tumor-free survival time is over 3 years.
For more information, please visit:
https://www.linkedin.com/company/juncell-therapeutics
Juncell Contact: